## **Become a Biotech or MedTech Entrepreneur** Agenda Planning for 2024 Course will begin at 8:30 am Saturday, June 1, 2024, and 8:30 am Sunday, June 2, 2024

Caturday June 1 2024 Day	a awawa Cabadada		
Saturday, June 1, 2024, Pro		Start Time	Time
Session 1: Opening Remarks, Program Overview	National Co-Chair:	8:30 am	30 minutes
SESSION 2. Crofting on Exit Strategy to Sotisfy	James Jordan, MBA, CHT Moderator and Lecturer:	9:00 am	20 minutos
SESSION 2: Crafting an Exit Strategy to Satisfy Stakeholders	James Jordan, MBA, CHT	9:00 am	30 minutes
Identifying optimal exit timing and valuation while	James Jordan, MDA, CITI		
balancing stakeholder interests of customers, investors,			
and acquirers.			
SESSION 3: Assessing if You Have a Project,	Moderator and Lecturer:	9:30 am	45 minutes
Product or Fundable Company	<u>John York, PhD</u>		
This session provides a framework for determining			
whether your company is a project, product, or			
platform based on IP foundations. Projects offer			
incremental improvements suited for licensing. Products enhance existing solutions but face adoption			
barriers. Fundable companies launch new categories			
poised for investment. We explore how these			
categories impact commercial potential and strategic			
value.			
Break		10:15 am	15 Minutes
Session 4: Crafting Winning Business Plans and	Moderator and Lecturer:	10:30 am	45 minutes
Investor Pitches	<u>Benjamin Chen, PhD</u>		
Covers best practices for creating compelling business			
plans and investment pitches tailored to audience			
needs, including problem/solution messaging, business model viability, team expertise and presentation tips.			
The session provides a framework for developing a			
pitch to investors/partners, and the essentials of a			
business plan.			
SESSION 5: Translating Strategy into Execution	Moderator and Lecturer:	11:15 am	45 minutes
with a Target Product Profile (TPP)	<u>Thanigavelan Jambulingam,</u>		
Details how a Target Product Profile bridges strategy	<u>PhD</u>		
and execution by outlining product specifications to			
meet clinical, customer, and market needs while			
aligning development, regulatory, pricing, IP, and commercialization efforts.			
This session provides the format and walks the student			
through how to prepare one for their firm.			
Lunch		12:00 pm	60 minutes
SESSION 6: Navigating Coding Systems and	Moderator and Lecturer:	1:00 pm	45 minutes
Optimizing Pricing and Reimbursement	Robert Wanerman, JD, MPH	1.00 piii	15 minutes
Reviews coding frameworks and pricing dynamics in			
regulated markets to equip entrepreneurs with			
knowledge on analyzing pricing potential, securing			
reimbursement, and planning profitable pricing			
strategies.			

CECCION 7- Democificion Democifica Democific	N4 - d t d   1 t	1 - 4 🗆	45
SESSION 7: Demystifying Regulatory Pathways	Moderator and Lecturer:	1:45 pm	45 minutes
for Market Entry	David T. Lin PhD		
Simplified overview of market entry requirements,			
highlighting product classification, clinical trial			
pathways, regulatory timelines/submissions, and tools			
like Product Development Plans to enable informed			
strategic planning.		2.20	45
Break			15 minutes
SESSION 8: Intellectual Property Mastery: From	Moderator and Lecturer:	2:45 pm	45 minutes
Fundamentals to Strategic Defense	<u>James Jordan, MBA, CHT</u>		
Actionable best practices around patents, IP strategy			
development, and communicating IP value to safeguard			
inventions, gain exclusivity, attract funding, and			
sustain competitive positioning.			
Session 9: Expert Q&A - Applying Frameworks to	Moderator:	3:30 pm	30 minutes
Your Venture	<u>Thanigavelan Jambulingam,</u>		
An interactive forum to get targeted advice from	<u>PhD</u>		
seasoned industry veterans on applying covered			
methodologies/frameworks to address participants'	Panel Members:		
specific innovation challenges.	Benjamin Chen, PhD		
	David T. Lin PhD		
	Robert Wanerman, JD, MPH		
SESSION 10: Building an Effective Board and	Moderator and Lecturer:	4:00 pm	30 minutes
Managing the Relationship	Thanigavelan Jambulingam,	4:00 pm	30 minutes
managing the Relationship	PhD		
Guidance on best practices for composing and	I TID		
leveraging boards of directors to effectively govern			
startups, emphasizing mutually accountable culture,			
balanced compositions, and navigating governance			
complexities.			
SESSION 11: De-Risking through Strategic	Moderator and Lecturer:	4:30 pm	30 minutes
Alliances	Kristina Zakurdaeva, MD, PhD	4.50 pm	50 minutes
Amances	Kristilia Zakurdaeva, MD, Frid		
Illustrates how startups can enhance credibility,			
accelerate momentum, and reduce perceived risk by			
strategically "borrowing" established brands'			
reputations via complementary partnerships.			
reputations via complementally partiferships.			
Session 12: Developing Your Investment Pitch	James Jordan, MBA, CHT	5:15 pm	15 minutes
(Homework)	James Jordany Fib. (7 Citt	3113 pm	15 milaces
Accionment to surft a some allies investigated at 19.1			
Assignment to craft a compelling investment pitch			
based on covered fundraising best practices and			
receive expert feedback.			

Sunday, June 2, 2023, Pro	gram Schedule	Start Time	Time
Session 13: Session 13: Presenting Your Pitch for Expert Feedback  Entrepreneurs present their full investment pitch developed as homework to get direct input from industry experts and investors in an interactive	National Co-Chair: James Jordan, MBA, CHT	8:30 am	30 minutes
SESSION 14: Building an Entrepreneurial Management Team  Explores team assembly challenges across startup stages through CEO and VC perspectives, emphasizing how executive team building and evolution impact funding decisions and the probability of success.	Moderator: John York, PharmD, MBA  David H. Crean, MBA Cardiff Advisory, LLC  Westbrook Weaver, PhD Founder, Chief Executive Officer Tempo Therapeutics, Inc www.tempothera.com  Patrik Schmidle CEO and Founder Cari Health  David Smith, JD  Stephanie Marrus	9:00 am	60 minutes
SESSION 15: Building Your Capitalization Strategy  Details early startup financing instruments and sources, including grants, angels, VCs, and partnerships. Reviews how to strategically fund innovation by understanding the motivations of diverse investor types.  - Non-Dilutive Funding – NIH - Angels - Corporate Venture Capital - Venture Capital - Corporate Partners	Moderator: Thanigavelan Jambulingam, PhD  Faculty: Steven M. Ferguson, MBA, CLP David Smith, JD  James E. Foley, PhD  Craig Shimasaki, PhD, MBA  Kristina Zakurdaeva, MD, PhD	10:15 am	60 minutes

CECCION 1C: Due cond (Cond Funding Ditch	Madayatay, Milsa Layadsa	11.15	CO resignates
SESSION 16: Pre-seed/Seed Funding Pitch	Moderator: Mike Lemcke	11:15 am	60 minutes
Entrepreneurs pitch and get feedback from investor	Presenting Company:		
panel on expectations, objections and handling early	Carlos Munoz		
startup fundraising and valuation dynamics.	Founder, ReBlood RX		
startap randraising and valuation dynamics.	rounder, <u>Rebiood IXX</u>		
	Panel Members:		
	Eddie Chung, MS		
	CEO, COASTAR Therapeutics,		
	Inc.		
	<u>Lu Yin Ph.D.</u>		
	CEO, Persperion, Inc.		
	Stephanie Allen		
	Entrepreneur in Residence		
	UC San Diego		
	Panjamin Chan DhD		
	<u>Benjamin Chen, PhD</u> <u>Vivian Lee</u> , PhD		
	viviaii Lee, Fiib		
Lunch		12:15 pm	60 minutes
SESSION 17: Early-Stage Funding Pitch	Madaratari Mika Lamaka	·	60 minutes
SESSION 17: Early-Stage Funding Pitch	Moderator: Mike Lemcke	1:15 pm	ou minutes
Later stage entrepreneurs receive investor feedback	Presenting Companies:		
on presenting more advanced funding requests,			
on presenting more advanced funding requests, including satisfying broader corporate partnership			
	Persperion Diagnostics Lu Yin Ph.D.		
including satisfying broader corporate partnership	Persperion Diagnostics		
including satisfying broader corporate partnership	Persperion Diagnostics <u>Lu Yin Ph.D.</u>		
including satisfying broader corporate partnership	Persperion Diagnostics <u>Lu Yin Ph.D.</u> CEO, Persperion, Inc.  Panel:		
including satisfying broader corporate partnership	Persperion Diagnostics <u>Lu Yin Ph.D.</u> CEO, Persperion, Inc.  Panel: <u>Matthew J. Bresnahan</u>		
including satisfying broader corporate partnership	Persperion Diagnostics <u>Lu Yin Ph.D.</u> CEO, Persperion, Inc.  Panel:		
including satisfying broader corporate partnership	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc. Panel: Matthew J. Bresnahan Partner, Wilson Sonsini		
including satisfying broader corporate partnership	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib,		
including satisfying broader corporate partnership	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc. Panel: Matthew J. Bresnahan Partner, Wilson Sonsini		
including satisfying broader corporate partnership	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals		
including satisfying broader corporate partnership	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher		
including satisfying broader corporate partnership	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director,		
including satisfying broader corporate partnership	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher		
including satisfying broader corporate partnership	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director, Entrepreneurship Initiatives San Diego State University		
including satisfying broader corporate partnership	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director, Entrepreneurship Initiatives San Diego State University  James E. Foley, PhD		
including satisfying broader corporate partnership interests requisite at Series A/B rounds.	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director, Entrepreneurship Initiatives San Diego State University		
including satisfying broader corporate partnership interests requisite at Series A/B rounds.  Break	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director, Entrepreneurship Initiatives San Diego State University  James E. Foley, PhD Bo Peng	2:15 pm	15 minutes
including satisfying broader corporate partnership interests requisite at Series A/B rounds.	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director, Entrepreneurship Initiatives San Diego State University  James E. Foley, PhD	2:15 pm 2:30 pm	15 minutes 45 minutes
including satisfying broader corporate partnership interests requisite at Series A/B rounds.  Break SESSION 18: Managing Media Relations	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director, Entrepreneurship Initiatives San Diego State University  James E. Foley, PhD Bo Peng  Moderator and Lecturer:		
including satisfying broader corporate partnership interests requisite at Series A/B rounds.  Break SESSION 18: Managing Media Relations  Highlights importance of crafting communications on	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director, Entrepreneurship Initiatives San Diego State University  James E. Foley, PhD Bo Peng  Moderator and Lecturer:  Moira A Gunn, PhD		
including satisfying broader corporate partnership interests requisite at Series A/B rounds.  Break  SESSION 18: Managing Media Relations  Highlights importance of crafting communications on biomedical advancements for mainstream	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director, Entrepreneurship Initiatives San Diego State University  James E. Foley, PhD Bo Peng  Moderator and Lecturer:  Moira A Gunn, PhD Host, NPR/BioTech Nation &		
including satisfying broader corporate partnership interests requisite at Series A/B rounds.  Break SESSION 18: Managing Media Relations  Highlights importance of crafting communications on biomedical advancements for mainstream consumption across digital channels to raise	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director, Entrepreneurship Initiatives San Diego State University  James E. Foley, PhD Bo Peng  Moderator and Lecturer:  Moira A Gunn, PhD Host, NPR/BioTech Nation & Director, Bioentrepreneurship,		1
including satisfying broader corporate partnership interests requisite at Series A/B rounds.  Break  SESSION 18: Managing Media Relations  Highlights importance of crafting communications on biomedical advancements for mainstream	Persperion Diagnostics Lu Yin Ph.D. CEO, Persperion, Inc.  Panel: Matthew J. Bresnahan Partner, Wilson Sonsini  Ruben Flores-Saaib, CEO, Regain Biomedicals  Cathy Pucher Executive Director, Entrepreneurship Initiatives San Diego State University  James E. Foley, PhD Bo Peng  Moderator and Lecturer:  Moira A Gunn, PhD Host, NPR/BioTech Nation &		1

SESSION 19: Structuring and Financing Your	Moderator and Lecturer:	3:15 pm	60 minutes
Venture			
	David Smith, JD		
Legal advisor reviews implications of entity			
structuring, governance, equity moves and exit			
scenarios across startup stages to equip leadership			
with operational, financing and capitalization acumen.			
SESSION 20: Program Wrap-up and Conclusion	<u>James Jordan, MBA, CHT</u>	4:15 pm	15 minutes
Faculty Office Happy Hours - this section provides		4:45 pm	
the opportunity of participants to interact and ask			
questions of the panelists			